Protagonist Therapeutics - Biotechkonzern im Fadenkreuz von Johnson & Johnson!
Geschäftstreiber: Protagonist Therapeutics (PTGS) hat sich auf die Entwicklung peptidbasierter Therapeutika spezialisiert, wobei man sich auf neue Ansätze zur Behandlung…
90,070$
0,23%
Echtzeit-Aktienkurs Protagonist Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Protagonist Therapeutics Inc. Aktie
Key deals this week: Protagonist Therapeutics, Bristol Myers, Novo Nordisk, Fifth Third Bancorp and more
…
Stocks making the biggest moves midday: MP Materials, Alibaba, Protagonist Therapeutics & more
These are the stocks posting the largest moves midday.…
Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports
Johnson & Johnson is in discussions to buy Protagonist Therapeutics , the Wall Street Journal reported on Friday, citing people…
Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports By Reuters
Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports…
Protagonist Therapeutics stock surges after J&J acquisition talks report
Protagonist Therapeutics stock surges after J&J acquisition talks report…
Protagonist (PTGX) Q2 Revenue Falls 26%
Key PointsGAAP loss per share of $0.55 in Q2 2025 beat analyst estimates by $1.13.GAAP revenue of $5.5 million in…
Protagonist Therapeutics: Two Slam Dunk Sets Of Pivotal Data Set Up Bull Case
…
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 62% and 149.90%, respectively, for the quarter ended March 2025. Do…
Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
The consensus price target hints at a 27.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this…
Protagonist Therapeutics (PTGX) Upgraded to Buy: Heres Why
Protagonist Therapeutics (PTGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to…
Protagonist Therapeutics: Transformation des Gesundheitswesens mit erstklassigen Peptidmedikamenten
Protagonist Therapeutics ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf die Entdeckung und Entwicklung von peptidbasierten Therapeutika konzentriert.…
Truist raises Protagonist Therapeutics target to $76 By Investing.com
Truist raises Protagonist Therapeutics target to $76…
4 Stocks to Buy for Attractive Earnings Acceleration
Invest in stocks such as Protagonist Therapeutics (PTGX), Evolus (EOLS), Western Digital (WDC), and Phunware (PHUN) as of now for…
4 Must-Buy Stocks for Remarkable Earnings Acceleration
Some of the notable companies to have witnessed solid earnings acceleration as of now are Protagonist Therapeutics (PTGX), AxoGen (AXGN),…